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METHODS

Study Design and Definitions
We conducted a retrospective study of patients with MDR-P. aeruginosa infections treated with ceftolozane-tazobactam at the University of Pittsburgh Medical Center from June 2015 to March 2016. MDR was defined by nonsusceptibility to ≥1 agent in ≥3 classes that are typically active against P. aeruginosa [26] . Types of infection were classified according to National Healthcare Safety Network criteria [27] . FDAapproved dosing was defined as compliance with the FDA label dosage for ≥5 days during the first week of therapy, regardless of the site of infection (1.5 g intravenously [IV] every 8 hours with adjustments for renal dysfunction and intermittent hemodialysis [iHD] ) [28] . Recent pharmacokinetic (PK) data suggest that 3 g IV every 8 hours may improve target attainment within pulmonary epithelial lining fluid (ELF) [29] . This dosage is being used in a phase 3 trial of ventilator-associated pneumonia (VAP) but it is not currently FDA approved for any indication [30] . PK-derived dosing was defined as compliance with the higher dosing regimen for respiratory tract infections (with renal adjustment) for ≥5 days during the first week of therapy. By these definitions, a patient with a creatinine clearance >50 mL/min treated for pneumonia with a dose of 1.5 g every 8 hours would be labelled as receiving FDAapproved dosing, whereas a patient treated with 3 g every 8 hours would be labelled as receiving PK-derived dosing. Since the phase 3 VAP trial excludes patients receiving any form of renal replacement therapy, we considered dosing for patients who had pneumonia but were on renal replacement therapy as "not defined" [30] .
Primary outcome was 30-day all-cause mortality. Secondary outcomes were 90-day all-cause mortality, 30-and 90-day attributable mortality, 90-day clinical failure, recurrent colonization, and emergence of resistance. Mortality was attributed to P. aeruginosa if the patient died with signs and symptoms of infection, microbiologic or histological evidence of an active P. aeruginosa infection, and if other potential causes of death were reasonably excluded. Although attributable mortality is often difficult to ascertain and definitions are controversial, we included it in the outcome analysis in order to compare our data with attributable mortality rates reported in previous studies of pseudomonal infection. Clinical failure was defined as attributable mortality due to P. aeruginosa, persistent signs or symptoms of infection or positive culture despite ≥7 days of ceftolozane-tazobactam, or recurrent P. aeruginosa infection (recurrent signs and symptoms and recurrent culture positivity within 90 days). Combination therapy was defined as receipt of ceftolozane-tazobactam plus ≥1 anti-pseudomonal drug for ≥72 hours. Acute kidney injury (AKI) was defined as ≥1.5-fold increase in serum creatinine from baseline. Ceftolozane-tazobactam resistance was defined as minimum inhibitory concentration (MIC) ≥16 µg/mL (E-test), in accordance with Clinical Laboratory and Standards Institute recommendations [31] . MICs for other agents were determined by MicroScan or disc diffusion.
Whole Genome Sequencing and Analysis
Full details of whole genome sequencing (WGS) and analysis are provided in the Supplementary Methods [32] . Susceptible isolates from 5 patients prior to ceftolozanetazobactam therapy were selected as ancestral strains for phylogenetic analyses. A P. aeruginosa genome most closely related to the consensus of the isolates (PA_BWHPSA022, as revealed by Mash [33] ) was used to determine phylogenetic relationships among isolates. Longitudinal isolates with preexisting (rather than emergent) ceftolozane-tazobactam resistance from a sixth patient were sequenced as controls (this patient is referred to as patient 22) . The genome of the founding isolate for each patient was the reference for identifying putative evolved mutations (single nucleotide polymorphisms [SNPs] , insertions-deletions [indels], and structural variants) in subsequent isolates by breseq [34] . Raw predicted mutations and filtered lists of mutations are reported in Supplementary Tables 1 and 2 . The filtered list, per patient, was curated to highlight genes that were categorically linked to β-lactam resistance in previous studies, including β-lactamases, efflux pumps, porins, and cell wall synthesis machinery [35] [36] [37] .
Quantitative Reverse Transcription-Polymerase Chain Reaction
DNase-treated RNA was obtained from late-exponential phase cultures in Luria broth at 37°C (RiboPure-Bacteria kit, ThermoFisher Scientific, Waltham, Massachusetts). cDNA was made using qScript cDNAMix (Quanta Biosciences, Gaithersburg, Maryland). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) of P. aeruginosa genes encoding common β-lactam resistance mechanisms, such as ampC, efflux genes mexB, mexD, mexY, and porin gene oprD, was performed using the Applied Biosystems 7900 system, with established primers (Supplementary Table  2 [38] [39] [40] ), and the SYBR Green kit (Quanta Biosciences, Maryland). Gene expression was normalized using rspL. Relative expression was calibrated against corresponding baseline ceftolozane-tazobactam susceptible isolates. qRT-PCR for all isolates was performed in at least triplicate on 3 separate days.
Statistical Analyses
Statistical analysis was performed using Stata 13.0 (College Station, Texas) and GraphPad Instat 3 (San Diego, California). Univariate analysis of contingency data was performed by 2-tailed χ 2 or 2-tailed Fisher exact tests. P < .05 was considered significant. 112 • CID 2017:65 (1 July) • Haidar et al
RESULTS
Patient Characteristics, Microbiology, and Treatment Regimens
Twenty-one patients were included (Table 1) . Nine patients (43%) were transplant recipients (7 lung, 1 lung-kidney, 1 stem cell). Twenty patients (95%) received an anti-pseudomonal antibiotic within 14 days prior to the index culture. Types of infection and susceptibility profiles are shown in Table 1 . Eighteen patients (86%) were treated for respiratory tract infections; the remaining 3 patients were treated for bacteremia, cIAI, or cUTI. Initial isolates were MDR but susceptible to ceftolozanetazobactam (median MIC, 1.5 µg/mL, range, 0.75-4 µg/mL). Fifteen (71%) of the initial isolates were resistant to all anti-pseudomonal β-lactams tested except ceftolozane-tazobactam. Six patients (29%) had coinfections with other pathogens (Table 2) . Median duration of therapy was 14 days (range, 3-52 days). Of 18 patients with respiratory tract infections, 5 (28%) received PK-derived dosages and 9 (50%) received FDA-approved dosages. Patients with nonrespiratory tract infections were treated with FDA-approved dosages. Four (22%) of 18 patients with respiratory tract infections were receiving renal replacement therapy, and a patient with primary bacteremia was receiving iHD ( Table 2 ); these are settings in which dosing is not defined. Sixteen (76%) patients received combination anti-pseudomonal therapy for ≥72 hours, including 2, 9, and 5 who received concomitant systemic, inhaled, and both systemic and inhaled agents, respectively ( Table 2 ).
Outcomes
The 30-day mortality rate was 10% (2/21) and the attributable mortality rate was 5% (1/21) ( Table 2 ). Corresponding 90-day rates were 48% (10/21) and 19% (4/21). Attributable 90-day mortality was due to persistent or recurrent MDR-P. aeruginosa pneumonia (patients 1, 6, 10, 11). In patient 11, ceftolozanetazobactam was discontinued after 3 days due to a rash.
The clinical failure rate of ceftolozane-tazobactam treatment was 29% (6/21). Clinical failures included the 4 patients with attributable deaths at 90 days, and 2 patients with MDR-P. aeruginosa pneumonia who survived to 90 days but developed recurrent pneumonia or suppurative tracheobronchitis (patients 4 and 8). Four patients who were successfully treated for pneumonia (patients 14 and 15), cIAI (patient 7), and cUTI (patient 18) were colonized by MDR-P. aeruginosa within 90 days of the index infection.
Ceftolozane-tazobactam resistance was identified in 3 patients (14%), emerging during recurrent pneumonia that led to death at 90 days (patient 1), airway colonization following intraabdominal infection (patient 7), and suppurative tracheobronchitis following pneumonia (patient 8). Resistance emerged 2 weeks after completion of a 30-day treatment course and on days 8 and 19 of treatment, respectively.
The only variable that was significantly associated with clinical failure was simplified acute physiology score-II (SAPS-II) score (median, 35 for failure and 23 for success; P = .04); there was a trend toward an association between clinical failure and age (median, 72.5 vs 58 years; P = .07). Site of infection, renal failure, combination vs monotherapy, use of inhaled therapy, time to initiation of ceftolozane-tazobactam, presence of coinfections, and FDA-approved or PK-derived dosing were not significantly associated with clinical failure or 90-day mortality. None of these factors were associated with emergence of ceftolozanetazobactam resistance. Thrombocytopenia occurred in 2 patients Cystic fibrosis 29 ( c Details in Table 2 .
d Ciprofloxacin and/or levofloxacin.
e Meropenem, imipenem, and/or doripenem.
f Colistin susceptibility testing is performed upon clinician request (10 isolates).
• CID 2017:65 ( This patient had primary bacteremia and was receiving intermittent hemodialysis; dosing for this situation is not established. patients 2 and 10) ; linezolid, either alone (patient 10) or with concomitant valganciclovir (patient 2), likely contributed to thrombocytopenia. No patient developed AKI attributable to ceftolozane-tazobactam. Ceftolozane-tazobactam was discontinued prematurely in only 1 patient (rash, patient 11).
Molecular Characterization of Longitudinal Isolates
Longitudinal isolates from patients in whom ceftolozanetazobactam resistance emerged (patients 7 and 8) and did not emerge (patients 4, 14, and 15) underwent WGS (Table  3) . Isolates clustered by patient, ruling out a common source of infection or transmission among patients (Figure 1 ) [41] . Isolates from different patients belonged to distinct multilocus sequence types (Supplementary Table 3 ). In each patient, infections clearly traced to a single founding strain ( Figure  1 ). The inferred genetic diversity among isolates within patients differed substantially, ranging from 2 to 98 unique SNPs (patients 4 and 8, respectively). More than 100 SNPs were observed in some isolates from patient 7, likely due to homologous recombination of an integrative conjugative element (details below; Supplementary Table 2) . Despite the variable genetic diversity, it was possible to identify mutations likely to be associated with gain of ceftolozane-tazobactam resistance that were not found in susceptible isolates. All isolates carried AmpC and OXA-50 β-lactamases but not other β-lactamases, ESBLs, or carbapenemases. However, only ceftolozane-tazobactam-resistant isolates harbored ampC mutations (Table 3 and Figure 2 ). Resistant isolates from patient 7 had 21-or 57-basepair deletions within ampC (Figure 2 ). Resistant isolates from patient 8 had point mutations in ampC (resulting in a threonine-to-isoleucine substitution at AmpC amino acid position 96 [T96I]) and the ampR-ampC intergenic region (Figure 2 ).
Resistant isolates from patient 7 also showed evidence of homologous recombination at the site of the integrative conjugative element mentioned above, which introduced >100 SNPs spanning 27 genes (including acrB, encoding a multidrug efflux pump subunit; Supplementary Table 3) [42] . Resistant isolates from patient 8 acquired a small indel mutation in oprD, the porin D precursor [43, 44] , and a nonsynonymous mutation G339E in multidrug efflux transporter mexB [45] . Two mutations in oprD were identified in a susceptible isolate (P14-S1) from patient 14. In addition, a mutation introducing a premature stop codon (Q45*) in quorum sensing regulator lasR was found in P14-S2 [46] . None of the isolates that remained susceptible had ampC mutations (Table 3) .
Three longitudinal isolates with preexisting ceftolozane-tazobactam resistance, recovered from a patient (patient [41] . The phylogeny was inferred from all informative single nucleotide polymorphisms in the core genome with FastTree, using the most closely related available reference genome, strain PA_BWHPSA022. All isolates definitively cluster by patient (P). Sensitivity or resistance to ceftolozane-tazobactam is denoted as S or R and timing of isolation is denoted by numbering (eg, for patient 7: P7-S, P7-R1, P7-R2, P7-R3, P7-R4). Distance bar = 0.2 nucleotide differences per phylogenetically informative site. Figure 2 . Diagram of mutations occurring in the ampR-ampC genomic region among resistant isolates. Mutation location, type, and proximity to the Ω-loop, known to confer resistance when mutated, is denoted. Orange box: nucleotides deleted in isolates from patient 7. Yellow box: domain encoding the Ω-loop. Abbreviation: bp, basepair.
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Expression of various genes previously implicated in β-lactam resistance was measured by qRT-PCR for isolates from patients 7 and 8. Compared to initial susceptible isolates, ceftolozane-tazobactam-resistant isolates P7-R2 and P8-R2 overexpressed ampC (30-fold and 4.4-fold, respectively; Table 4 ). In contrast, there was no change in ampC expression by P7-R1 compared to P7-S. Compared to P8-S, isolate P8-R2 also overexpressed efflux pump transporter genes mexY and, to a lesser extent, mexB and mexD (3.2-fold, 1.9-fold, and 1.7-fold, respectively). There were no differences in oprD expression between initial and susceptible isolates from either patient 7 or patient 8.
DISCUSSION
This study reports real-world experience with ceftolozanetazobactam treatment of MDR-P. aeruginosa infections, which was directed largely against respiratory tract infections rather than FDA-approved indications of cIAI and cUTI. By some measures, treatment appeared to be effective. Thirty-day allcause mortality, the primary outcome in this study, was only 10%. Moreover, 30-and 90-day attributable mortality rates of 5% and 19%, respectively, were lower than rates of 42%-56% previously reported for MDR-P. aeruginosa infections, including pneumonia in the intensive care unit, hospital-acquired pneumonia, and VAP [47] [48] [49] . Ceftolozane-tazobactam was also well tolerated, as premature drug discontinuation was necessary in a single patient. By other measures, however, results were more equivocal. The low 30-day mortality rate was consistent with that predicted by median SAPSII and SOFA (sequential organ failure assessment) scores [50, 51] . Clinical failure of treatment at 90 days, defined as a composite of attributable mortality, or persistent or recurrent infection, was 29%. Most worrisome was our finding that resistance emerged in 3 patients (14%), as quickly as 8 days into treatment. More reports on treatment responses and resistance during various types of MDR-P. aeruginosa infections are needed to put our experience in context and define ceftolozane-tazobactam's place in the armamentarium.
Several factors may have mitigated ceftolozane-tazobactam responses among our patients. First, our cohort was comprised of patients with a variety of complex medical conditions, including 9 transplant recipients (43%), 8 patients (38%) with ventilator-dependent respiratory failure, 7 patients (33%) who had undergone recent surgery, and 5 patients (24%) who were receiving renal replacement therapy (24%). Second, 16 patients (76%) were treated for pneumonia, a disease characterized by high microbial burdens and unpredictable antibiotic PK at sites of infection. Third, 6 patients (29%) were coinfected with other pathogens, which may have contributed to outcomes. Finally, clinicians often avoided adding antibiotics such as aminoglycosides and colistin, which were also active against infecting isolates but limited by toxicity concerns. Indeed, it is well recognized that antibiotic activity is not the sole determinant of outcomes in patients with MDR-P. aeruginosa infections. The importance of host factors in this study was underscored by the finding that elevated SAPS-II score was the only significant risk factor for clinical failure.
Ceftolozane-tazobactam dosing was not significantly associated with patient outcomes or emergence of resistance, but our study size may have limited the ability to establish relationships. Only 5 (28%) patients with respiratory tract infections received a PK-derived dose, which is double the FDA-approved dose. In healthy volunteers, the FDA-approved dose achieves ELF concentrations that exceed 8 mg/L for >60% of the dosing interval [52] . Recently, however, investigators using Monte Carlo simulations predicted that the probability of ceftolozane-tazobactam pharmacokinetic-pharmacodynamic Multidrug efflux pump mexY
Significant difference in expression between sensitive and resistant isolates was defined as >1.5-fold and P < .05 by analysis of variance.
Baseline ampC expression by control strains Pseudomonas aeruginosa PAO1 and ATCC 27853 was at the limit of detection (data not shown), which limited the ability to precisely define the extent to which expression by clinical isolates from patients 7 and 8 (P7-S1, P8-S1) was increased. (PK-PD) target attainment within ELF was 98% with the PK-derived dose compared to 88% with the FDA-approved dose [28] . In a brief report, the higher dosage was effective in treating 3 patients with MDR-P. aeruginosa pneumonia [53] . We currently advocate the PK-derived dosage for treatment of respiratory infections. There are no approved dosing recommendations for patients who receive continuous renal replacement therapy for any type of infection or for patients with pneumonia undergoing iHD. To our knowledge, this is the first study to use WGS to characterize evolution of antibiotic resistance in longitudinal MDR-P. aeruginosa isolates recovered during the course of infection. Phylogenetic analysis of WGS data demonstrated that ceftolozane-tazobactam resistance evolved independently in index isolates from 2 patients. By detecting mutations and measuring transcription of genes linked to β-lactam resistance, we identified several potential resistance mechanisms. First among these was constitutive overexpression of ampC by resistant isolates (P7-R2, P8-R2) compared to respective index isolates. De-repressed P. aeruginosa mutants account for large proportions of isolates that are broadly resistant to β-lactams [13, [54] [55] [56] and archived isolates with preexisting ceftolozane-tazobactam resistance [13] . It is plausible that ampC is induced and/or de-repressed by more efficient binding of the ampR regulatory factor, as has been reported with ampR-ampC intergenic point mutations (as observed in resistant isolates from patient 8) [55, 57] .
Other possible ceftolozane-tazobactam resistance determinants included ampC deletions, as seen in patient 7, and amino acid substitutions that impact the β-lactamase Ω-loop ( Figure 2 ). The Ω-loop comprises the substrate binding site and represents a hot spot for mutations that enhance catalytic efficiency and extend the spectrum of β-lactamase activity [15] . Various Ω-loop mutations widen the substrate binding site, thereby facilitating adherence and hydrolysis of β-lactams with bulky side chains such as ceftolozane and other oxyiminocephalosporins [15, 58] . The H215Y substitution in resistant isolates from control patient 22 fell within the Ω-loop. The T96I substitution in resistant isolates from patient 8 occurred within the H2 helix, which lies close to the serine active site and interacts with the Ω-loop through hydrogen binding [59] . H2 helix mutations can render the active-site serine more pliable, opening the Ω-loop entrance to accommodate larger cephalosporins such as ceftolozane [58] . Longitudinal isolates with retained ceftolozane-tazobactam susceptibility did not carry ampC mutations, whereas ampC mutations were evident in isolates with preexisting ceftolozane-tazobactam resistance. These observations lend credence to the conclusion that such mutations contributed to resistance.
Constitutive overexpression of mexY, mexB, and mexD (which encode cytoplasmic membrane transporters for efflux pumps), presence of a mexB G339E mutation, acquisition of multidrug efflux gene acrB, and acrB mutations were observed in various ceftolozane-tazobactam-resistant isolates. It is unclear if upregulation and/or acquisition of efflux systems may overcome the fact that ceftolozane is a weak efflux substrate [13, 60] .
Our study is limited by its single-center, retrospective design and its small sample size. Clinical findings and resistant isolates may not be representative of those from other institutions or countries. Our interpretation of the effectiveness of ceftolozane-tazobactam is limited by the lack of a control group treated with other anti-pseudomonal agents. We also acknowledge that the genetic diversity we described in longitudinal isolates may reflect both bona fide variation in evolutionary dynamics and error in sequencing and bioinformatics analyses.
In conclusion, ceftolozane-tazobactam is an important advance in the treatment of MDR-P. aeruginosa infections, but more clinical data are needed to understand its place in the armamentarium. The emergence of resistance after short courses of therapy in some patients highlights the importance of establishing strict criteria for the drug's use and the continued need for new antibiotics. Studies are needed to understand the role of combination therapy, define ceftolozane-tazobactam PK during different types of infection, validate dosing regimens derived from PK-PD data, and verify resistance mechanisms.
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